CB1 antagonists for obesity–what lessons have we learned from rimonabant? 28 May Dr D Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.